Premium
Tumor Therapy: In Situ Tumor Vaccination with Nanoparticle Co‐Delivering CpG and STAT3 siRNA to Effectively Induce Whole‐Body Antitumor Immune Response (Adv. Mater. 31/2021)
Author(s) -
Ngamcherdtrakul Worapol,
Reda Moataz,
Nelson Molly A.,
Wang Ruijie,
Zaidan Husam Y.,
Bejan Daniel S.,
Hoang Ngoc Ha,
Lane Ryan S.,
Luoh ShiuhWen,
Leachman Sancy A.,
Mills Gordon B.,
Gray Joe W.,
Lund Amanda W.,
Yantasee Wassana
Publication year - 2021
Publication title -
advanced materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.707
H-Index - 527
eISSN - 1521-4095
pISSN - 0935-9648
DOI - 10.1002/adma.202170244
Subject(s) - immune system , cancer research , materials science , immunotherapy , antigen , cancer immunotherapy , vaccination , cancer , immunology , medicine
In article number 2100628, Wassana Yantasee and co‐workers investigate how Augmenting Immune Response and Inhibiting Suppressive Environment of tumors‐02 (AIRISE‐02) activates an antitumor immune response. AIRISE‐02 is a nanoparticle co‐delivering STAT3 siRNA and CpG intratumorally, utilizing local tumor antigens to train the immune system to kill cancer throughout the body. AIRISE‐02 shows strong efficacy in various tumor models, and favorable safety in mice and monkeys.